PRPHProPhase Labs, Inc.

Nasdaq prophaselabs.com


$ 5.38 $ 0.11 (2.07 %)    

Friday, 03-May-2024 15:59:50 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 5.42
$ 5.37
$ 0.00 x 0
$ 0.00 x 0
$ 5.37 - $ 5.43
$ 4.05 - $ 9.94
38,391
na
97.81M
$ 0.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-12-2023 03-31-2023 10-Q
5 03-29-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-12-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-13-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
14 11-19-2020 09-30-2020 10-Q
15 08-11-2020 06-30-2020 10-Q
16 05-12-2020 03-31-2020 10-Q
17 03-26-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-12-2019 06-30-2019 10-Q
20 05-14-2019 03-31-2019 10-Q
21 03-26-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-20-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 03-28-2018 12-31-2017 10-K
26 11-13-2017 09-30-2017 10-Q
27 08-11-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 02-24-2017 12-31-2016 10-K
30 11-15-2016 09-30-2016 10-Q
31 08-11-2016 06-30-2016 10-Q
32 05-13-2016 03-31-2016 10-Q
33 03-29-2016 12-31-2015 10-K
34 11-13-2015 09-30-2015 10-Q
35 08-12-2015 06-30-2015 10-Q
36 05-13-2015 03-31-2015 10-Q
37 03-27-2015 12-31-2014 10-K
38 11-13-2014 09-30-2014 10-Q
39 08-12-2014 06-30-2014 10-Q
40 05-12-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 prophase-labs-unveils-project-zenq-ai-leveraging-prophase-labs-ai-platform-massive-genomics-database-and-patented-esophageal-cancer-insights-for-antibody-drug-conjugates-development

Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug ...

 prophase-labs-seeks-to-transform-esophageal-cancer-detection-and-management-with-launch-of-its-be-smart-test-in-h2-2024

ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagn...

 prophase-labs-q4-eps-051-misses-026-estimate-sales-435m-miss-1069m-estimate

ProPhase Labs (NASDAQ:PRPH) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.2...

 earnings-scheduled-for-march-15-2024

Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report quarterly loss at $0.10 per share on re...

 hc-wainwright--co-reiterates-buy-on-prophase-labs-maintains-11-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $11 price target.

 prophase-labs-announces-progress-in-be-smart-esophageal-cancer-test-development-uspto-grants-additional-broad-patents-for-be-smart

ProPhase Labs, Inc. (NASDAQ:PRPH), a next generation biotech, genomics and diagnostics company, today announced important devel...

 prophase-labs-announces-progress-at-pharmaloz-manufacturing-accelerating-expansion-improves-pricing-boosts-profitability-and-secures-new-contracts

Pharmaloz Wins Two New Contracts in January that are Anticipated to Significantly Increase Lozenge Revenues and ProfitabilityCo...

 prophase-poised-to-ramp-up-growth-at-pharmaloz-and-nebula-genomics-in-2024-company-announces-the-hiring-of-long-time-industry-veteran-jed-latkin-as-coo-to-help-build-and-manage-this-growth

Company also plans to commercialize its BE-Smart Esophageal Cancer Test in 2024Company announces the hiring of long-time indust...

 hc-wainwright--co-maintains-buy-on-prophase-labs-lowers-price-target-to-11

HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and lowers the price target from $1...

 prophase-labs-q3-eps-030-misses-020-estimate-sales-837m-miss-1306m-estimate

ProPhase Labs (NASDAQ:PRPH) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.2...

 earnings-scheduled-for-november-9-2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on re...

 prophase-labs-earnings-preview
ProPhase Labs Earnings Preview
11/08/2023 17:01:29

 prophase-labs-inc-says-pharmaloz-plan-is-to-build-capacity-with-a-goal-to-attain-a-revenue-run-rate-of-60-to-80m-by-year-end-2024-pharmaloz-is-projected-to-achieve-a-run-rate-of-15m-in-annualized-revenues--run-rate-of-3m-in-gross-profit-during-q1

- Reuters

Core News & Articles

DSS, Inc. (NYSE:DSS), a multinational company operating nine (9) diversified business lines developed through strategic acquisi...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 99 stocks hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-monday

  During Monday, 102 stocks hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-monday

  During Monday's session, 201 stocks hit new 52-week lows.

 hc-wainwright--co-reiterates-buy-on-prophase-labs-maintains-14-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $14 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION